Peter Murray, Editor

About the Author Peter Murray, Editor


Top Analyst Sets Expectations on Facebook (FB) Ahead of Today’s 2Q:18 Earnings

Social giant Facebook (NASDAQ:FB) is set to release its quarterly earnings report after the closing bell today, which might give investors pause after …

Applied Optoelectronics (AAOI) Will Be Most Vulnerable to the $200B Chinese Tariff Proposal; Analyst Reiterates a Neutral Rating on the Stock

The pain continues for fiber-optic component maker Applied Optoelectronics (NASDAQ:AAOI), which has struggled over the past year with slowing orders for its parts …

Top Analyst on Broadcom (AVGO)-CA Technologies Deal; Bull vs. Bear Debate

Broadcom (NASDAQ:AVGO), which tried and failed to buy rival chip maker Qualcomm (NASDAQ:QCOM) for $117 billion, is now attempting to buy software maker …

Twitter Inc (TWTR): The Work Gets Harder From Here

BMO Capital analyst Daniel Salmon is out today with a research note on shares of Twitter Inc (NYSE:TWTR), after the social media giant topped the Street’s …

NXT-ID Inc (NXTD) Stock Can Reach $6: Brian Kinstlinger

Maxim’s Brian Kinstlinger: The recent capital raise is a significant positive event for NXTD.

Teva Pharmaceutical Industries Gets FDA Priority Review for Fremanezumab, Putting It a Month Behind Amgen in Race for Migraine Market

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has secured a priority review at the FDA for its fremanezumab’s BLA for prevention of migraine. Securing a …

Roku Inc (ROKU) 3Q Earnings Give This Top Analyst a Bit More Confidence

Mark Mahaney believes the company is executing on its long-term vision, but remains sidelined.

Top Analyst Pounds the Table on Activision Blizzard, Inc. (ATVI)

Piper Jaffray’s top analyst Michael Olson was out pounding the table on shares of Activision Blizzard, Inc. (NASDAQ:ATVI) Friday, reiterating an Overweight rating and price …

Alibaba Group Holding Ltd (BABA) Nailed It Again; Top Analyst Reiterates Buy

Alibaba Group Holding Ltd (NYSE:BABA) reported another strong set of headline earnings, with results well above consensus expectations, including accelerating revenue growth, driven …

Maxim Reiterates Buy On ContraVir Pharmaceuticals Inc (CTRV) Following Corporate Update

Maxim analyst Jason Kolbert is out today with a new research note on shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), following the company’s third-quarter results and …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts